Global Bronchitis Treatment Market, By Type (Acute Bronchitis and Chronic Bronchitis), By Treatment (Drugs and Oxygen Therapy), By Drug Class (Anti-Inflammatory Drugs, Antibiotics, Bronchodilators, Mucolytic), By Route of Administration (Oral, Parenteral, Inhalers/Nasal sprays, Others), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024

Code : CMI7208

Pages :173

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Global Bronchitis Treatment Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing Air Pollution Worldwide

Increasing air pollution worldwide can drive the global bronchitis treatment market growth. As per World Health Organization (WHO), around 7 million people die every year due to air pollution exposure globally. Air pollution is one of the leading causes of chronic respiratory diseases like bronchitis, which damages the lungs over a long period of exposure to polluted air. Bronchitis causes inflammation in the bronchial tubes of lungs which leads to coughing, wheezing and shortness of breath.

Rising vehicular and industrial emission levels have tremendously deteriorated the air quality across major cities worldwide. According to the data from IQAir's 2021 World Air Quality Report, India had the highest annual average particulate matter (PM2.5) levels among the most polluted countries in the world. PM2.5 can easily enter deep into lungs and bloodstream, thus, increasing the risk of bronchitis and other lung diseases. China also witnessed sharp rise in air pollution levels post COVID lockdowns with most cities reporting unhealthy and hazardous air quality on daily basis. The growing population, urbanization and climate change has augmented the ground level ozone and other harmful pollutants concentration in the atmosphere. This surge in air pollution has led to exponential growth in bronchitis patient base worldwide. According to a study published by Global Asthma Network, Bangladesh witnessed over 50% increase in moderate to severe asthma cases among adults from 2010 to 2018, mostly attributed to air pollution. Rising disease incidence has boosted demand for bronchitis diagnostics, therapeutics and symptom management products globally. The market is witnessing increased adoption of combination therapies involving corticosteroids, antibiotics and bronchodilators.

Key Players Insights